These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16158409)

  • 1. A model for immunological correlates of protection.
    Dunning AJ
    Stat Med; 2006 May; 25(9):1485-97. PubMed ID: 16158409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laboratory investigation of immune responses to acellular pertussis vaccines when used for boosting adolescents after primary immunisation with whole cell pertussis vaccines: a comparison with data from clinical study.
    Reynolds E; Walker B; Xing D; Southern J; Asokanathan C; Dagg B; Corbel M; Miller E
    Vaccine; 2006 Apr; 24(16):3248-57. PubMed ID: 16480794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary immunization with a triple diphtheria-tetanus-whole cell pertussis vaccine in Iranian infants: an analysis of antibody response.
    Zarei S; Jeddi-Tehrani M; Akhondi MM; Zeraati H; Pourheidari F; Ostadkarampour M; Tavangar B; Shokri F
    Iran J Allergy Asthma Immunol; 2009 Jun; 8(2):85-93. PubMed ID: 19671937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
    Zepp F; Habermehl P; Knuf M; Mannhardt-Laakman W; Howe B; Friedland LR
    Vaccine; 2007 Jul; 25(29):5248-52. PubMed ID: 17583395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Administration of tetanus, diphtheria, and acellular pertussis vaccine to parents of high-risk infants in the neonatal intensive care unit.
    Dylag AM; Shah SI
    Pediatrics; 2008 Sep; 122(3):e550-5. PubMed ID: 18762489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice.
    Geurtsen J; Banus HA; Gremmer ER; Ferguson H; de la Fonteyne-Blankestijn LJ; Vermeulen JP; Dormans JA; Tommassen J; van der Ley P; Mooi FR; Vandebriel RJ
    Clin Vaccine Immunol; 2007 Jul; 14(7):821-9. PubMed ID: 17494641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody levels to Bordetella pertussis in 10-yr-old children with atopy and atopic asthma.
    Blanco-Quiros A; Garcia-Marcos L; Garrote JA; Martinez-Torres AE; Leon A
    Pediatr Allergy Immunol; 2005 Dec; 16(8):637-40. PubMed ID: 16343084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactogenicity and immunogenicity profiles of a novel pentavalent diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type B vaccine: a randomized dose-ranging trial of the Hib tetanus-conjugate content.
    Hla KH; Thein SA; Aye A; Han HH; Bock HL; David MP; Schuerman L
    Pediatr Infect Dis J; 2006 Aug; 25(8):706-12. PubMed ID: 16874170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules.
    Pichichero ME; Casey JR; Francis AB; Marsocci SM; Murphy M; Hoeger W; Cleary C
    Clin Pediatr (Phila); 2006 Sep; 45(7):613-20. PubMed ID: 16928838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on adolescent immunization: review of pertussis and the efficacy, safety, and clinical use of vaccines that contain tetanus-diphtheria-acellular pertussis.
    Wilson TR
    J Pediatr Health Care; 2006; 20(4):229-37. PubMed ID: 16831630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population.
    Knuf M; Zepp F; Meyer C; Grzegowski E; Wolter J; Riffelmann M; Wirsing von König CH
    Vaccine; 2006 Mar; 24(12):2043-8. PubMed ID: 16356597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content.
    Hendrikx LH; Berbers GA; Veenhoven RH; Sanders EA; Buisman AM
    Vaccine; 2009 Nov; 27(47):6530-6. PubMed ID: 19729085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
    Zangwill KM; Eriksen E; Lee M; Lee J; Marcy SM; Friedland LR; Weston W; Howe B; Ward JI
    Pediatrics; 2008 Dec; 122(6):e1179-85. PubMed ID: 19047220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Common vaccine antigens inhibit allergen-induced sensitization and airway hyperresponsiveness in a murine model.
    Grüber C; Gerhold K; von Stuckrad SL; Avagyan A; Quarcoo D; Ahrens B; Wahn U; Hamelmann E
    Allergy; 2006 Jul; 61(7):820-7. PubMed ID: 16792579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine as a single-dose booster in Singaporean adults.
    Chan SH; Tan PT; Han HH; Bock HL
    Singapore Med J; 2006 Apr; 47(4):286-90. PubMed ID: 16572239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of pertussis immune responses to tetanus-diphtheria-acellular pertussis vaccine in health care personnel: implications for outbreak control.
    Kirkland KB; Talbot EA; Decker MD; Edwards KM
    Clin Infect Dis; 2009 Aug; 49(4):584-7. PubMed ID: 19589084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of pertussis vaccine efficacy using a correlates of protection model.
    Kohberger RC; Jemiolo D; Noriega F
    Vaccine; 2008 Jun; 26(27-28):3516-21. PubMed ID: 18495303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New immunizations for adults.
    Harv Mens Health Watch; 2006 Oct; 11(3):5-6. PubMed ID: 17153759
    [No Abstract]   [Full Text] [Related]  

  • 20. Statement on the recommended use of pentavalent and hexavalent vaccines. An Advisory Committee Statement (ACS).
    National Advisory Committee on Immunization (NACI)
    Can Commun Dis Rep; 2007 Feb; 33(ACS-1):1-14. PubMed ID: 17294559
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.